最新数据：多线治疗无效后，CAR-T为患者带来71.4%临床获益率 摘要356：CLDN18.2 chimeric antigen receptor T cell therapy for patients with advanced gastric and pancreatic adenocarcinoma: Results of ELIMYN18.2 phase 1b clinical trial.研究背景：自体抗CLDN18.2（CLDN18.2）CAR-T细胞，即satri-cel（CT...
Chávez, J.C., Bachmeier, C.A. and Kharfan‐Dabaja, M.A. (2019) 'CAR T-cell therapy for B-cell lymphomas: clinical trial results of available products,' Therapeutic Advances in Hematology, 10, p. 204062071984158. https://doi.org/...
16. Kochenderfer JN, Dudley ME, Feldman SA, et al. B-cell depletion and remissions of malignancy along with cytokine-associated toxicity in a clinical trial of anti-CD19 chimeric-antigen-receptor-transduced T cells [J]. Blood, 2012, 119(12): p. 2709-20. doi: 10.1182/blood-2011-10-38...
CD20-Targeted Autologous CAR T Therapy. Retrieved June 16, 2023 from https://www.globenewswire.com/news-release/2023/06/15/2689364/0/en/Mustang-Bio-Announces-Final-Results-from-Follicular-Lymphoma-Cohort-of-Single-Institution-Phase-1-2-Clinical-Trial-...
New Interim Soquelitinib Data from its Phase 1/1b T Cell Lymphoma Trial. Retrieved December 11, 2023, from https://www.globenewswire.com/news-release/2023/12/09/2793436/0/en/Corvus-Pharmaceuticals-Presents-New-Interim-Soquelitinib-Data-from-its-Phase-1-1b-T-Cell-Lymphoma-Trial.html ...
2024年美国临床肿瘤学会(ASCO)上,我国北京大学肿瘤医院研究团队以口头报告形式公布了“satri-cel(一款CLDN18.2-CAR-T细胞产品),治疗胃肠道肿瘤的1期临床试验的最终结果”,这是首个应用CLDN18.2-CAR-T细胞治疗实体瘤的临床研究数据,相关结...
CAR-T疗法在血液肿瘤临床治疗上取得成功案例激励着学界努力摸索新的免疫细胞疗法。近几年,自然杀伤细胞(natural killer cell,NK) 成为下一个被基因工程改造的对象。NK细胞是一种天然免疫细胞,具有与T细胞完全不同的靶细胞识别方式,能泛特异性识别并杀死瘤细胞。外周血中大约90% NK细胞为 CD16+CD56dim亚群,表面表达...
Christine E. Brown et al. Locoregional delivery of IL-13Rα2-targeting CAR-T cells in recurrent high-grade glioma: a phase 1 trial. Nature Medicine, 2024, doi:10.1038/s41591-024-02875-1. City of Hope-developed chimeric antigen receptor (CAR) T cell therapy shows clinical activity in pati...
最新数据:多线治疗无效后,CAR-T为患者带来71.4%临床获益率 摘要356:CLDN18.2 chimeric antigen receptor T cell therapy for patients with advanced gastric and pancreatic adenocarcinoma: Results of ELIMYN18.2 phase 1b clinical trial. 研究背景:自体抗CLDN18.2(CLDN18.2)CAR-T细胞,即satri-cel(CT041),被...
A multicenter retrospective study that evaluated the efficacy and safety of chimeric antigen receptor (CAR) T-cell treatment, axicabtagene ciloleucel (axi-cel; Yescarta), in a real-world setting produced a similar response as well as toxicity compared with the ZUMA-1 clinical trial results. ...